%PDF-1.4
%
59 0 obj
<>
endobj
56 0 obj
<>
endobj
118 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-02-02T15:59:13Z
2024-03-28T18:21:32-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T18:21:32-07:00
application/pdf
Heather
2004-74.feb
uuid:1f490712-1dd2-11b2-0a00-120927fd5800
uuid:1f490715-1dd2-11b2-0a00-6a0000000000
endstream
endobj
45 0 obj
<>
endobj
46 0 obj
<>
endobj
60 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 27 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 29 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 31 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 33 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 35 0 R/Type/Page>>
endobj
18 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 37 0 R/Type/Page>>
endobj
21 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 39 0 R/Type/Page>>
endobj
144 0 obj
[148 0 R]
endobj
145 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
12 789 587 -785 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 73.368 737.5293 Tm
[(type II phospholipase )54.8 (A2 \(PLA2\) transgenic mice provide a tool to)]TJ
0 -1.25 TD
(determine the role of PLA2 in inflammatory conditions [abstract].)Tj
T*
(Arthritis Rheum 1996;38 Suppl:S293.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Grass DS, Felkner RH, Chiang MY)128.8 (, et al. Expression of human)]TJ
2.175 -1.25 Td
(group II PLA2 in transgenic mice results in epidermal hyperplasia)Tj
T*
(in the absence of inflammatory infiltrate. J Clin Invest)Tj
0 Tc 0 Tw T*
(1996;97:2233.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Garcia Pastor P)110.7 (, De Rosa S, De Giulio )54.8 (A, Paya M, )54.8 (Alcaraz MJ.)]TJ
2.1381 -1.25 Td
(Modulation of acute and chronic inflammatory processes by)Tj
T*
(cacospongionolide B, a novel inhibitor of human synovial )Tj
T*
[(phospholipase )54.8 (A2. Br J Pharmacol 1999;126:301-1)36.8 (1.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (Lin MK, Farewell )17.7 (V)128.9 (,)-0.1 ( )17.7 (V)110.8 (adas P)110.7 (,)-0.1 ( Bookman )54.8 (AA, Keystone EC,)]TJ
2.175 -1.25 Td
[(Pruzanski )17.7 (W)91.8 (. Secretory phospholipase )54.8 (A2 as an index of disease)]TJ
T*
(activity in rheumatoid arthritis. Prospective double blind study of)Tj
T*
[(212 patients. J Rheumatol 1996;23:1)36.8 (162-6.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Jamal OS, Conaghan PG, Cunningham )54.8 (AM, Brooks PM, Munro)]TJ
2.175 -1.25 Td
[(VF)79.7 (, Scott KF)79.7 (. Increased expression of human type IIa secretory )]TJ
T*
[(phospholipase )54.8 (A2 antigen in arthritic synovium. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(1996;57:550-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(14.)-875.1 (Nevalainen )17.7 (TJ, Marki F)79.7 (, Kortesuok PT)73.9 (, Grutter MG, Di Marco S,)]TJ
2.175 -1.25 Td
[(Schmitz )54.8 (A. Synovial type \(group II\) phospholipase )54.8 (A2 in cartilage.)]TJ
T*
(J Rheumatol 1993;20:325-30.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Pruzanski )17.7 (W)91.8 (, Bogoch E, Katz )54.8 (A, et al. Induction of release of )]TJ
2.175 -1.25 Td
[(secretory nonpancreatic phospholipase )54.8 (A2 from human articular)]TJ
T*
[(chondrocytes. J Rheumatol 1995;22:21)36.8 (14-9.)]TJ
-2.175 -1.25 Td
[(16.)-875.1 (Minami )17.7 (T)74 (,)-0.1 ( )17.7 (T)69.9 (ojo H, Shinomura )36.8 (Y)128.9 (, Matsuzawa )36.8 (Y)128.9 (, Okamoto M.)]TJ
2.175 -1.25 Td
[(Increased group II phospholipase )54.8 (A2 in colonic mucosa of patients)]TJ
T*
[(with Crohn\325)54.8 (s disease and ulcerative colitis. Gut 1994;35:1593-8.)]TJ
-2.175 -1.25 Td
[(17.)-875.1 (Green J-A, Smith GM, Buchta R, et al. Circulating phospholipase)]TJ
2.175 -1.25 Td
(A2 activity associated with sepsis and septic shock is )Tj
T*
(indistinguishable from that associated with rheumatoid arthritis.)Tj
T*
(Inflammation 1991;15:355-67.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
2.175 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-2.175 -1.25 Td
[(19.)-875.1 (Hochber)17.7 (g MC, Chang R)54.8 (W)91.9 (, Dwosk I, et al. )17.7 (The )54.8 (American College)]TJ
2.175 -1.25 Td
(of Rheumatology 1991 revised criteria for the classification of)Tj
T*
[(global functional status in rheumatoid arthritis. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1992;35:498-502.)Tj
-0.00011 Tc 0.02499 Tw 30.825 47.5 Td
[(20.)-875.1 (Fries JF)79.7 (, Spitz, Kraines RG, Holman HR. Measurement of patient)]TJ
2.175 -1.25 Td
[(outcome in arthritis. )54.8 (Arthritis Rheum 1980;23:137-45.)]TJ
-2.175 -1.25 Td
[(21.)-875.1 (Prevoo ML, )17.7 (V)110.8 (an Riel PL, )17.7 (V)110.8 (an \324T)-257.3 (Hof MA, et al. )17.7 (V)110.8 (alidity and )]TJ
2.175 -1.25 Td
[(reliability of joint indices. )54.8 (A)-220.1 (longitudinal study in patients with)]TJ
T*
(recent onset rheumatoid arthritis. Br J Rheumatol )Tj
0 Tc 0 Tw T*
(1993;32:589-94.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(22.)-875.1 (Felson DT)73.9 (, )54.8 (Anderson JJ, Boers M. )54.8 (American College of)]TJ
2.175 -1.25 Td
(Rheumatology preliminary definition of improvement in )Tj
T*
[(rheumatoid arthritis. )54.8 (Arthritis Rheum 1995;38:727-35.)]TJ
-2.175 -1.25 Td
[(23.)-875.1 (V)110.8 (adas P)110.8 (, Browning J, Edelson J, et al. Extracellular phospholipase)]TJ
2.175 -1.25 Td
(A2 expression and inflammation: the relationship with associated)Tj
T*
(disease states. J Lipid Mediat 1993;8:1-30.)Tj
-2.175 -1.25 Td
[(24.)-875.1 (T)69.9 (ada K, Murakami M, Kambe )17.7 (T)74 (, Kudo I. Introduction of )]TJ
2.175 -1.25 Td
[(cyclooxygenase-2 by secretory phospholipase )54.8 (A2 in nerve growth)]TJ
T*
[(factor)19.7 (-stimulated rat serosal mast cells is facilitated by interaction)]TJ
T*
(with fibroblasts and mediated by a mechanism independent of their)Tj
T*
(enzymatic functions. J Immunol 1998;161:5008-15.)Tj
-2.175 -1.25 Td
[(25.)-875.1 (Pruzanski )17.7 (W)91.9 (,)-0.1 ( )17.7 (V)110.8 (adas P)110.8 (, Stefanski E, Urowitz MB. Phospholipase )54.8 (A2)]TJ
2.175 -1.25 Td
(activity in sera and synovial fluids in rheumatoid arthritis and)Tj
T*
(osteoarthritis. Its possible role as a proinflammatory enzyme. )Tj
T*
[(J Rheumatol 1985;12:21)36.8 (1-6.)]TJ
-2.175 -1.25 Td
[(26.)-875.1 (Kim KP)110.7 (, Rafter JD, Bittova L, et al. Mechanism of human group )17.7 (V)]TJ
2.175 -1.25 Td
[(phospholipase )54.8 (A2 \(PLA2\)-induced leukotriene biosynthesis in)]TJ
T*
[(human neutrophils. J Biol Chem 2001;276:1)36.8 (1)36.8 (126-34.)]TJ
-2.175 -1.25 Td
[(27.)-875.1 (Roshak )54.8 (A, Mochan E, Marshall LA. Suppression of human synovial)]TJ
2.175 -1.25 Td
[(fibroblast 85 KDa phospholipase )54.8 (A2 by antisense reduces )]TJ
T*
(interleukin-1\247 induced prostaglandin E2. J Rheumatol )Tj
0 Tc 0 Tw T*
(1996;23:420-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(28.)-875.1 (Amandi-Bur)17.7 (germeister E, )17.7 (T)35 (ibes U, Kaiser BM, Friebe )17.7 (WG,)]TJ
2.175 -1.25 Td
[(Scheuer )17.7 (WV)128.8 (. Suppression of cytokine synthesis, integrin expression)]TJ
T*
(and chronic inflammation by inhibitors of cytosolic phospholipase)Tj
T*
(A2. Eur J Pharmacol 1997;326:237-50.)Tj
-2.175 -1.25 Td
[(29.)-875.1 (Bondeson J, Sundler R. )54.8 (Antimalarial drugs inhibit phospholipase)]TJ
2.175 -1.25 Td
(A2 activation and induction of interleukin 1 beta and tumor )Tj
T*
(necrosis factor alpha in macrophages: implications for their mode)Tj
T*
(of action in rheumatoid arthritis. Gen Pharmacol 1998;30:357-66.)Tj
ET
0 0 0 1 K
52.97 77 m
557.97 77 l
S
0 0 0 0 k
493.79 69.86 64.18 -15.66 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tc 0 Tw 8 0 0 8 544.968 56.9344 Tm
(423)Tj
ET
0 0 0 0 k
53.03 70.6 203 -18.85 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.032 56.6859 Tm
[(Bradley)54.8 (, et al: T)54.8 (rial of L)19.7 (Y333013 and PLA)]TJ
0 Tc 0 Tw 6 0 0 6 191.7172 54.0459 Tm
(2)Tj
ET
0 0 0 0 k
/GS0 gs
104.13 81.75 407.5 -10.83 re
f*
0.5 w
104.13 81.75 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_2 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
39 0 obj
<>stream
8;Z\76#ORo%-.@PW:(.!/q`en^(:Cs
mF^!ATG3[B<9t3r3AS^,*FBNU\H'TFlZk:C?eRAF@l+rbfU#!M=Hi^&XQJJC")bY)
O[d7b3@;b2],ur)0)ABd2FXCC[1(2*8>rsu"-i0bF&]j2[:Qqk#)OD^B1<=FAeNs!
+VDU)5Z2-BgTurrKEtQpPo\VB:2MTK9.48TMe0i68F';s7A?DI?)iJHV8:(0Sc+Eg
/).)kg=(2CHo[N,dDfQhaZQ*-?;m7qYF)Gcjtj^kUVRalF1Q6;g^%a#[RWER8d1DB
Ce!%!R84<#=]KHK%<;t*,n6Ug0H'](A^&===71[K+V`b2mIY]Gb9rbS.\,'/@iEk:
>GPjJ+Cs?aZO*aWI)s_D+MVYT2Q]hH\b/%7DJtT<^%0)6*Wq^h.0C>)O<7F%[pQfe
QH7/MLL+<7!(E_u-=VD!n!.S.<6J>"5ufJ>h/g*(8UdoO9[S^iU]U-$2?']]*2RuX
eIs<*S2bNJ`/,-TVLdXF4NZ($GOa["W^f:mcYr7cZhPF=gi(HZ~>
endstream
endobj
43 0 obj
[/Indexed/DeviceRGB 255 42 0 R]
endobj
42 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
74 0 obj
<>
endobj
67 0 obj
<>
endobj
103 0 obj
<>
endobj
123 0 obj
<>
endobj
65 0 obj
<>
endobj
97 0 obj
<>stream
H|TyPgfpiۈQh"
x+" 0 #0\d$QA@@dQ\
xE%X4c|T6&lW{ᘹky ĪunT1]K%&843xHYۣ(I B
u9;?S`*;sw;>!UX8w~zNZOw+">\oN%cu]ڄx*I1bbx:_Skw/5:^'iUX6jRԼ/0^kDnoNQi5j߫}1\\ǦavVt)Hy`"[Nc[0o{#LyO/V3{-Y,i|c6CLIò',^ZfZZYY+NqR7'yMVo{.̮K9L}=5`Bߵrx/9-w:ìgn(y^ԫp^
$7c`C0
'={ QEaw* =sYչ}bdy0z9#-fS^yn=/M\1"KQ5GrׇnW4.UI':,ٚյI[{i<8NT0T=mPrinMmg.hhrUUl"
yDC>')E4tЋwCsœk H |6HH6WM4j&}-';VzoK@aqX &:d`upT7gXΐ!P!Zޖ +ȭE?;Tְ0C$*KKkrQҥ=đ3܂lٙ;wnwƄS#`6.\wV)) @-_gF70]
6?6n׆u{
6!r(%i +Hڄ
}45XS|W֭CBgep᧑gMa7Cij7a)3Sb|sJȻY
_+(
Z*LOz`(!Qz. S_"X8G@I >I%t
%)zpx=(uC:B@qDd{`9[w*%gś!WS?∍sU)t
TK5Uo>pybjx_j֧(HyŎ:ՌjP=ֱs07V`9yybӣQ!Z.tQ"!9D{SCdqdėb'*{6ozctlQ-0Qzs-0CعUnB\ofuyh&3PH6W3sԛs`)8m}><6$s
g$N$rb)Rui4|"_ dl4z=6%Ð3ڊV8#|H2G"3lX嬂7\'@qK=jyGϦʶmbHϓGxⅶ>&Vє.VDO}z^"ju(4>Gz,EwNPU#,۩BLSW~Jp&X?QϔUqU=t]fJ-Yɉ@vAFKeUbzUT,A
`֠`Q>\9@:C$%D^H*jtHg(g䊈ې3rE w(%|H96TBdA
, pT,K71D&
=SqÆJ鎒R#sPIuADq!ٕTH:4BQLd/ܤTހFr<7b)+R#Ϫ]霦,:'/
#{Xd3>m]zaHޤWEK(*LNE3,5po2=*י590DjOHL5RkQ4
TD
˲\r(EAEE[ Ѩͱ5bjygoӿg<={0OpH[57S֠7Q~ÈOBS~]!X",j
3dM"
CQ0̐NtsD\ljDHь;0?-AP%b2M8>CZt]v'#W^.D 6
NA(xp=&!|bQ
ahVHD]˱.VvA+uws%
nʥ2E,0 N܁͇-QPrhazn[{ܒU`n|1P6
g9ok0SYza呓Z*ɳdFQ;j҇"|!Z˶NVSSe5ÐC>!O+ӫ8+ثny`D+SU),ڻNeP&
>naC';ӄ'=]DJXUJ{};R6c(.p|g
ˠ%GuJꜶI(SG2V]-Eٷ``-&МJΩ'9FD8zLfۙ&k
?ڳ
_5*}*h/߉atG3.
qې]Iru&
4dzkJvfWژ3
dCY0oc
s4P=Ngf+Z0|M,C49v2c{Jꌮ'%{
xZSMGZkue;;e@:963DiF[qyf?. ٭.+k~iT$iV'ڨKFn#P_LH*αNsXȚ*P|Itϣ"d"Z\nY]ASR^MCR\NO2%Y{Z%,{ŐE8HW8CID{>k<*7u3:[Ë[6
VN8:'w]^'X[8)(ǩ]m@JAHF3<ȿ8R;i)ôTf3ml /?^IB`쀙/jYw t=V=7%M^AkP>L]A4^H+ 1
{(! ;5ǺcYeO!XǴm?5ԧvq'A"R=cI´C[WP&RgMaD{;! Z]@0ZiL@dHb
KR_@T#퍨*
;,t$=[I/BW&N<.?w߇Ws_wT!U҃_(,QˤB=)rl%+~"`|ڕڝ|6~PQn-`&D9j,֎+R㱼xĽ}y36sᅿvgzFnEK:f]:c)
TMpyjuOy/Sk_'hycsC"G.]XlHfXi嚓s~; KzCg/A$"k!({tlKը7Y